Front. Immunol. Frontiers in Immunology Front. Immunol. 1664-3224 Frontiers Media S.A. 10.3389/fimmu.2025.1741271 Correction Correction: Receptor tyrosine kinase inhibitor sunitinib as novel immunotherapy to inhibit myeloid-derived suppressor cells for treatment of endometriosis HeYing 1 Investigation Writing – original draft Formal analysis Data curation Methodology Writing – review & editing HungSze Wan 1 Writing – review & editing LiangBo 1 Writing – review & editing ZhangRuizhe 1 Writing – review & editing GaoYating 1 Writing – review & editing ChuChing Yan 1 Writing – review & editing ZhangTao 1 Writing – review & editing XuHui 1 Writing – review & editing ChungJacqueline Pui Wah 1 Writing – review & editing WangChi Chiu 1 2 3 4 * Conceptualization Writing – review & editing Project administration Writing – original draft Supervision Data curation Formal analysis Funding acquisition Department of Obstetrics & Gynaecology, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, China Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, China School of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, China Chinese University of Hong Kong–Sichuan University Joint Laboratory in Reproductive Medicine, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, China Correspondence: Chi Chiu Wang, ccwang@cuhk.edu.hk 24 11 2025 2025 16 1741271 07 11 2025 12 11 2025 Copyright © 2025 He, Hung, Liang, Zhang, Gao, Chu, Zhang, Xu, Chung and Wang. 2025 He, Hung, Liang, Zhang, Gao, Chu, Zhang, Xu, Chung and Wang https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. A Correction on Receptor tyrosine kinase inhibitor sunitinib as novel immunotherapy to inhibit myeloid-derived suppressor cells for treatment of endometriosis By He Y, Hung SW, Liang B, Zhang R, Gao Y, Chu CY, Zhang T, Xu H, Chung JPW and Wang CC (2021). Front. Immunol. 12:641206. doi: 10.3389/fimmu.2021.641206 endometriosis myeloid-derived suppressor cells Sunitinib immunosuppression gene expressions section-at-acceptance Cancer Immunity and Immunotherapy

An incorrect Funding statement was provided. The correct Funding statement reads:

“This research was supported by The Hong Kong Obstetrical & Gynaecological Trust Fund 2019 from Hong Kong Society of Obstericians and Gynaecologists; Academic Equipment Grant (3029876); and Direct Grant (2017.044) from The Chinese University of Hong Kong.”

The original version of this article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland